Rheumatology

Tumor necrosis factor receptor 1 associated periodic syndrome (TRAPS): A Patient Guide

At a Glance

TRAPS is a rare genetic condition that causes inflammatory flares lasting one to three weeks, often with fever, rash, moving muscle pain, and eye swelling. IL-1-blocking treatment plus regular inflammation and kidney tests can help prevent organ damage from AA amyloidosis.

Tumor Necrosis Factor Receptor 1 Associated Periodic Syndrome (TRAPS) is a rare genetic condition that fundamentally changes how the body’s immune system responds. Unlike an infection caused by bacteria or a typical autoimmune disease where the body produces antibodies against itself, TRAPS is an autoinflammatory disease ^[1].

In this condition, a mutation in the TNFRSF1A gene alters a critical immune receptor (TNFR1). The exact biological mechanism depends on the specific variant. For certain high-penetrance variants, the receptor “misfolds” inside the cell, creating cellular stress that essentially short-circuits the body’s inflammatory pathways ^[2]. This causes the immune system to trigger intense inflammatory responses that can occur spontaneously, though some patients report they are precipitated by physical or emotional stress.

The hallmark of living with TRAPS is the experience of unusually prolonged inflammatory flares. While other periodic fever syndromes might cause symptoms that vanish in a few days, a TRAPS flare typically lasts for one to three weeks ^[3]. During these episodes, patients often face a distinct constellation of symptoms, including high fevers, a red rash, and a unique type of muscle pain (migratory myalgia) that moves from one part of the body to another. Many also experience periorbital edema, a characteristic swelling and redness around the eyes ^[4]. Because these flares are long-lasting, they can significantly disrupt daily life, education, and career.

Managing TRAPS has been transformed by modern medicine’s ability to target specific inflammatory messengers. For patients who need maintenance therapy, contemporary treatment strategies focus on blocking a signaling molecule called Interleukin-1 (IL-1) ^[5]. By quieting this specific pathway, doctors can often stop flares and, more importantly, reduce the background level of inflammation that can persist between active episodes ^[6].

The ultimate goal of this specialized care is to protect the body’s vital organs. The most serious long-term risk in TRAPS is a condition called AA amyloidosis, where inflammatory proteins build up in the organs—particularly the kidneys—causing permanent damage ^[7]. Because this baseline inflammation can be active even when you feel well, regular laboratory monitoring of inflammatory markers like Serum Amyloid A (SAA) and routine kidney function tests are an essential part of long-term care ^[8]. By combining specialized medical expertise with consistent monitoring, people with TRAPS can look forward to a future focused on well-being and the prevention of complications ^[9].

In this guide

6 chapters

Understanding Your TRAPS Diagnosis

Understand a TRAPS diagnosis, including TNFRSF1A variants, flare symptoms, inheritance, specialist care, and monitoring for AA amyloidosis and kidney damage.

TRAPS Symptoms, Flares, and Warning Signs

Learn about tumor necrosis factor receptor 1 associated periodic syndrome (TRAPS): flare patterns, triggers, symptoms, and warning signs needing urgent care.

Genetics, Variants, and How TRAPS is Diagnosed

Learn how TRAPS is diagnosed, what TNFRSF1A variants mean, and how symptoms, flare length, and mosaicism help distinguish it from similar fever syndromes.

Treatment Strategy and Medications for TRAPS

Learn how TRAPS treatment works, including IL-1 inhibitors, on-demand medicines, TNF inhibitor warnings, infection safety, and SAA tests for long-term control.

Monitoring and Long-Term Health with TRAPS

Learn how TRAPS monitoring helps prevent AA amyloidosis, detect kidney damage early, track inflammation, and support healthy growth in children over time.

Building Your Care Team and Preparing for Visits

Learn how to build a TRAPS care team and prepare for specialist visits with genetic reports, flare diaries, inflammation labs, family history, and kidney checks.

Common questions in this guide

What is TRAPS, and what causes it?

TRAPS is a rare genetic autoinflammatory condition, meaning the immune system can cause inflammation without a typical infection. It is linked to variants in the TNFRSF1A gene, which affects the TNFR1 immune receptor.

What do TRAPS flares feel like, and how long do they last?

TRAPS flares usually last one to three weeks, longer than many other periodic fever syndromes. Common symptoms include high fever, a red rash, muscle pain that moves from place to place, and swelling or redness around the eyes.

Can stress trigger a TRAPS flare?

TRAPS flares can occur without an obvious trigger, but some people report that physical or emotional stress comes before an episode. Tracking possible triggers and symptoms may help you and your clinician recognize patterns, although a reported trigger does not prove it caused the flare.

How is TRAPS treated between flares?

For people who need ongoing treatment, medicines that block interleukin-1 (IL-1) can reduce flares and the inflammation that may continue between episodes. Your clinician uses your symptoms, genetic variant, and laboratory results to decide whether maintenance biologic treatment is appropriate.

Why are Serum Amyloid A and kidney tests important in TRAPS?

Inflammation can remain active even when you feel well, and high levels of Serum Amyloid A can signal ongoing inflammatory activity. Regular inflammation and kidney-function tests help clinicians watch for AA amyloidosis, a buildup of protein that can permanently damage the kidneys.

When should someone with TRAPS see a nephrologist?

Ask your healthcare team whether a nephrologist should be involved if your variant or laboratory results suggest concern about kidney complications such as AA amyloidosis. Nephrology follow-up can support regular assessment of kidney function alongside your TRAPS care.

Can TRAPS cause symptoms between flares?

Yes. Baseline inflammation can continue even when an obvious flare has ended, and some people may notice less visible symptoms or an ongoing effect on daily life. Regular monitoring can help identify inflammation that you may not feel.

Curated prompts to bring to your next appointment.

1.How do my specific symptoms and genetic variant compare to the typical presentation of TRAPS?
2.What is our long-term plan for monitoring my baseline inflammation even when I am not having a flare?
3.Based on my variant and lab results, should I be referred to a nephrologist to monitor for long-term complications like amyloidosis?
4.How will we decide when my treatment needs to be adjusted from 'on-demand' relief to a maintenance biologic?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References (9)

1
Comparison of the clinical diagnostic criteria and the results of the next-generation sequence gene panel in patients with monogenic systemic autoinflammatory diseases.
Sözeri B, Demir F, Sönmez HE, et al.
Clinical rheumatology 2021; (40(6)):2327-2337 doi:10.1007/s10067-020-05492-8.
PMID: 33165748
2
A rare missense p.C125Y mutation in the TNFRSF1A gene identified in a Chinese family with tumor necrosis factor receptor-associated periodic fever syndrome.
Qian M, Zhou J, Wu J, et al.
Frontiers in genetics 2024; (15()):1413641 doi:10.3389/fgene.2024.1413641.
PMID: 38978873
3
[Periodic fever syndrome associated with mutations in the TNF type 1 receptor gene: A differential diagnosis of familial Mediterranean fever that should not be overlooked in patients of Mediterranean origin].
Bourguiba R, Savey L, Aouba A, et al.
La Revue de medecine interne 2021; (42(7)):459-464 doi:10.1016/j.revmed.2020.08.007.
PMID: 33131906
4
Efficacy of anakinra in an adult patient with recurrent pericarditis and cardiac tamponade as initial manifestations of tumor necrosis factor receptor-associated periodic syndrome due to the R92Q TNFRSF1A variant.
Camprubí D, Mitjavila F, Arostegui JI, Corbella X
International journal of rheumatic diseases 2017; (20(4)):510-514 doi:10.1111/1756-185X.13029.
PMID: 27990755
5
International Retrospective Chart Review of Treatment Patterns in Severe Familial Mediterranean Fever, Tumor Necrosis Factor Receptor-Associated Periodic Syndrome, and Mevalonate Kinase Deficiency/Hyperimmunoglobulinemia D Syndrome.
Ozen S, Kuemmerle-Deschner JB, Cimaz R, et al.
Arthritis care & research 2017; (69(4)):578-586 doi:10.1002/acr.23120.
PMID: 27723279
6
The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist.
Romano M, Arici ZS, Piskin D, et al.
Annals of the rheumatic diseases 2022; (81(7)):907-921 doi:10.1136/annrheumdis-2021-221801.
PMID: 35623638
7
Tumour necrosis factor receptor-1 associated periodic syndrome (TRAPS)-related AA amyloidosis: a national case series and systematic review.
Delaleu J, Deshayes S, Rodrigues F, et al.
Rheumatology (Oxford, England) 2021; (60(12)):5775-5784 doi:10.1093/rheumatology/keab252.
PMID: 33715002
8
Revisiting TNF Receptor-Associated Periodic Syndrome (TRAPS): Current Perspectives.
Cudrici C, Deuitch N, Aksentijevich I
International journal of molecular sciences 2020; (21(9)) doi:10.3390/ijms21093263.
PMID: 32380704
9
The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist.
Romano M, Arici ZS, Piskin D, et al.
Arthritis & rheumatology (Hoboken, N.J.) 2022; (74(7)):1102-1121 doi:10.1002/art.42139.
PMID: 35621220

This page is for informational purposes only and does not constitute medical advice. Your healthcare team should interpret your TRAPS symptoms, genetic variant, treatment plan, and kidney-monitoring results.

Get notified when new evidence is published on Tumor necrosis factor receptor 1 associated periodic syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents